Kelun Biotech, a subsidiary of Shenzhen-listed Kelun Pharmaceutical, has secured approximately 4 billion yuan ($581 million) from its parent firm and a slew of notable investors, according to a filing on the Shenzhen Stock Exchange on Friday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
